NeoGenomics (NEO) Could Be 24% Below Fair Value As Losses Narrow in Q3

NeoGenomics (NEO) moved back into focus after reporting third quarter 2026 results, with sales of US$209.25 million and a reduced net loss of US$7.55 million compared with the prior year period.

NeoGenomics’ latest earnings update landed as the share price pulled back 3.1% on the day, while the stock remains up 47.8% year to date and has delivered a 77.8% total shareholder return over twelve months. This points to momentum that has cooled slightly in the past month but remains strong over the year as investors reassess both growth potential and risk after the reduced losses reported for 2026 so far.

Capitalize on NeoGenomics’ renewed interest by scanning a curated set of healthcare diagnostics players in our 34 healthcare AI stocks, which could be primed for their own rerating.

Bulls will point to NeoGenomics’ shrinking losses and strong 12 month return. Bears will flag the still loss making profile and volatile recent pullback. Which story does the current valuation actually support?

Most Popular Narrative: 24% Undervalued

NeoGenomics last closed at $17.38 while the most followed narrative points to a fair value near $22.89, so the current share price sits well below the modeled outcome that analysts are using to frame the recent repricing case.

Investments in new digital pathology capabilities, automation, and the integration of a unified LIMS are expected to generate material operating efficiencies and enable greater operating leverage, supporting future expansion in EBITDA margins and earnings growth.

See why 6 investors see NeoGenomics as 24% undervalued.

Result: Fair Value of $22.89 (UNDERVALUED)

Still, the whole NeoGenomics rerating case hinges on clinical demand holding up, while pharma related revenue pressure and ongoing RaDaR litigation do not erode the margin story.

Find out about the key risks to this NeoGenomics narrative.

Another View On NeoGenomics’ Valuation

The analyst narrative frames NeoGenomics as roughly 24% undervalued against a modeled fair value of $22.89, yet the market is assigning a very different message through sales based multiples. At about 2.9x P/S, the stock trades well above the US Healthcare sector on 1.3x and peers on 1.4x, and also above an estimated fair ratio of 1.5x, which points to a richer entry point than the headline undervaluation suggests. So which signal do you treat as the anchor when you think about the risk on the next $1 of upside or downside?

To pressure test that gap, it helps to see what the numbers say about this price in our valuation breakdown, then compare where NeoGenomics sits against other cancer testing businesses using the same yardstick See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

Conflicting signals on NeoGenomics can make any verdict feel uncertain. Move quickly past headline impressions to your own assessment by reviewing the 2 important warning signs.

Ready To Find Your Next Idea Beyond NeoGenomics?

If NeoGenomics has your attention, do not stop at one ticker. Broaden your watchlist now so you are not chasing opportunities after they move.

• Pinpoint potential bargains with stronger fundamentals by scanning our 33 high quality undervalued stocks before other investors focus on them.
• Strengthen your downside protection by reviewing companies with resilient finances using the list of solid balance sheet and fundamentals (24 results).
• Spot early stage potential by checking out a curated set of under followed candidates through the 19 high quality undiscovered gems.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com